Abstract:This study explores the impact of enzymatically modified isoquercitrin (EMIQ) on photoaging induced by UVA and UVB exposure through both in vitro and clinical assessments. In vitro experiments conducted on HDFa cells under UVA exposure reveal that EMIQ mitigates ROS levels and modulates the expression of MMP1, TGFβR2, Smad7, and COL1A1. Building on this, the effects of EMIQ on full‐thickness T‐SkinTM subjected to UVA + UVB were examined. Clinical findings over a 28‐day facial test indicate significant improvements in skin texture, TWEL, R2, and Ra metrics. This research examines the anti‐aging potential of the flavonoid derivative of isoquercitrin known as enzymatically modified isoquercitrin (EMIQ). Initial HPLC analyses showed that EMIQ used in the study contained 1–12 glucosides and 10.7% pentahydroxyflavonoids, promising potent antioxidant properties. In subsequent in‐vitro studies with UVA‐exposed human dermal fibroblasts (HDFa), EMIQ demonstrated protective properties by reducing collagen damage. It modulated both the TGFβ/Smad pathway and the MMP1 pathway, contributing to collagen preservation. This protective effect was further confirmed using the T‐SkinTM model, a reconstructed full‐thickness human skin model, which illustrated that EMIQ could defend the physiological structures of both the epidermis and dermis against UV radiation. A 28‐day clinical trial with 30 volunteers aged 31–55 years highlighted EMIQ's effectiveness. Participants using EMIQ‐containing Essence displayed reduced facial trans‐epidermal water loss and skin roughness, alongside improved skin elasticity. This study emphasizes EMIQ's potential as an anti‐photoaging ingredient in cosmetics, warranting further research. The findings pave the way for developing innovative skincare products addressing photoaging effects.

Enzymatically modified isoquercitrin and its protective effects against photoaging: In‐vitro and clinical studies